Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Cancer J. 2013 Jul-Aug;19(4):10.1097/PPO.0b013e31829d74b4. doi: 10.1097/PPO.0b013e31829d74b4

Figure 3.

Figure 3

Schema outlining the proposed mechanisms of action of sunitinib. Although sunitinib is well known to inhibit angiogenesis, abrogation of MDSC recruitment to tumor sites by sunitinib may promote the antitumor immune response, suggesting an alternative mechanism of action.